Esperion Therapeutics, Inc. (ESPR)
2.86
+0.10
(+3.62%)
USD |
NASDAQ |
Mar 26, 16:00
2.86
0.00 (0.00%)
After-Hours: 16:40
Esperion Therapeutics Cash from Investing (Quarterly) : 0.00 for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Nektar Therapeutics | 0.372M |
| Harrow, Inc. | -4.73M |
| Catalyst Pharmaceuticals, Inc. | -0.032M |
| Rigel Pharmaceuticals, Inc. | -25.36M |
| CytomX Therapeutics, Inc. | -14.42M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 45.24M |
| Cash from Financing (Quarterly) | 30.16M |
| Free Cash Flow | -13.09M |
| Free Cash Flow Per Share (Quarterly) | 0.159 |
| Free Cash Flow to Equity (Quarterly) | 98.23M |
| Free Cash Flow to Firm (Quarterly) | 67.22M |
| Free Cash Flow Yield | -2.08% |